El interés en corto de aTyr Pharma da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de aTyr Pharma. Los datos de interés en corto se actualizan cada dos semanas.

aTyr Pharma (NASDAQ:ATYR) Bolsa, Informe de interés en corto

aTyr Pharma

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

aTyr Pharma Inc

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is currently trading near our key level of 561.90. Bulls need to maintain strength above this level, targeting an initial move toward 563.23. If buying pressure sustains, we expect a further rally to 564.29. Holding this level as support could pave the way for an advance to 565.38, with strong momentum pushing SPY toward our high bull target of 566.46.
Should 561.90 fail to hold as support, we anticipate sellers driving the price lower to 560.83. If weakness persists, a test of 559.75 is likely. Breaking below this level could accelerate downside momentum, bringing 558.32 into play. If the selling intensifies, our low bear target for the session sits at 557.44.
Invesco QQQ Trust Series 1 (QQQ)
QQQ is currently trading around 479.03. Bulls want to see price action sustain above this level, allowing a push to 481.73. If buyers maintain control, 483.95 comes into focus as the next key level. Should bullish momentum remain intact, we anticipate a continuation to 486.10, with strong upside potentially bringing QQQ to our high bull target of 487.69.
If QQQ struggles to stay above 479.03, sellers could push the price down to 476.85. Continued weakness may result in a test of 474.66. A further breakdown exposes 471.33, and if bearish pressure remains dominant, the market could reach our low bear target of 469.27.
Apple Inc. (AAPL)
Apple is currently positioned around 212.44. Bulls need to establish this level as firm support to initiate an upward move toward 214.07. Continued strength in buying could push AAPL toward 215.25. If buyers sustain their momentum, we expect a breakout higher, targeting our high bull objective of 216.70.
If 212.44 fails to hold, sellers will likely push AAPL lower to 211.12. Further downside pressure could test 209.81, with a continued decline exposing 208.81. Should the selling intensify, our low bear target for Apple sits at 207.93.
Microsoft Corp. (MSFT)
Microsoft is currently trading near 386.09. Bulls need to defend this level and push the price higher toward 387.60. If this level holds as solid support, we anticipate a continued rally to 388.53. Strong bullish action could carry MSFT to our high bull target of 389.29.
If 386.09 fails as support, bears may drive the price down to 385.42. If selling persists, a move to 384.57 is likely. Should further downside pressure emerge, we anticipate a drop toward 382.69, with aggressive selling potentially driving MSFT to our low bear target of 379.50.
NVIDIA Corporation (NVDA)
NVIDIA is currently trading around 123.41. Bulls need to sustain strength above this level, with an initial move targeting 125.21. If buying momentum continues, the next key resistance stands at 126.84. Should the uptrend hold, NVDA could rally toward 128.10, with further strength pushing it to our high bull target of 129.53.
If 123.41 fails to hold as support, sellers will likely push the price down to 121.97. A break below this level could lead to a test of 120.27. If selling pressure accelerates, 119.44 becomes the next major support. A sustained bearish move could drive NVDA to our low bear target of 117.86.
Alphabet Inc Class A (GOOGL)
Alphabet is currently trading near 165.41. Bulls need to hold this level as support to sustain upward momentum. If buyers step in, the first upside target is 167.04. Continued strength in the auction could drive the price toward 169.34, which is our high bull target for the day.
If 165.41 is lost as support, bears will look to take control and push the price lower toward 163.79. A breakdown at this level could lead to further selling pressure, with a potential move down to 161.79. In a more aggressive sell-off, Alphabet may test the low bear target at 160.36.
Meta Platforms Inc (META)
Meta is currently trading near 609.30. Bulls need to keep price action above this level to target an initial move to 615.65. If bullish sentiment strengthens, 622.01 becomes the next upside level. Sustained buying could push META toward our high bull target of 629.88.
If 609.30 fails as support, bears may push the price down to 604.50. If sellers remain aggressive, we anticipate further downside toward 598.17. A breakdown below this level could send META to our low bear target of 591.29.
Tesla Inc. (TSLA)
Tesla is currently trading near 246.16. Bulls need to push the price above this level, setting up an initial target at 248.37. If the buying momentum remains strong, we anticipate a move toward 250.25. Continued bullish sentiment could drive Tesla higher to 252.38, with an extended rally reaching our high bull target of 254.28.
If 246.16 fails as support, sellers may attempt to take control and drive the price down to 243.98. Continued weakness could lead to a test of 242.49. If selling pressure intensifies, Tesla may drop to our low bear target of 239.92.
Final Word:
Today's session kicks off with the release of February&#8217;s Advance Retail Sales at 8:30 AM ET, accompanied by the Empire State Manufacturing Index for March. At 10:00 AM ET, the Business Inventories report for January will be published alongside the NAHB Housing Market Index for March. Additionally, at 11:30 AM ET, the U.S. Treasury will conduct a 3 and 6 month Bill Auction. With the FOMC rate decision on Wednesday and contract roll week in full swing, we anticipate heightened volatility. Stay sharp, manage risk effectively, and trade smart!
The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day—hours before it&#8217;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Broad U.S. Equity ETFs

Technicals

Signals

Pre-Market Outlook

How To Trade The SPY: Retail Sales in Focus

B of A Securities analyst Ken Hoexter maintains JB Hunt Transport Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) with a Buy and lowers the price target from $189 to $170.

News

Price Target

Analyst Ratings

JBHT

B of A Securities Maintains Buy on JB Hunt Transport Servs, Lowers Price Target to $170

Shares of Chinese EV charging service provider, NaaS Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) are <a href="https://www.benzinga.com/premarket">trading higher in premarket</a> on Monday.
The company has formed a <a href="https://www.benzinga.com/pressreleases/25/03/n44351825/naas-technology-inc-and-xiaomi-auto-join-forces-to-enhance-smart-ev-charging-ecosystem">strategic partnership with Xiaomi Auto</a>, a branch of Xiaomi Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACY#OTC">XIACY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>). The collaboration aims to transform the EV charging landscape by merging NaaS&#8217;s vast charging network with Xiaomi Auto&#8217;s advanced mobility technology. 
The aim is to deliver efficient AI-powered charging solutions across the country for Xiaomi EV users who can now access NaaS's extensive network through the Xiaomi Auto app and in-vehicle navigation systems, simplifying the process of locating charging stations. 
The initiative seeks to optimize the charging experience and provide real-time, intelligent solutions, catering to the expanding NEV market in China.
Also Read: <a href="https://www.benzinga.com/25/03/44330842/why-is-visionary-holdings-stock-surging-today">Visionary Holdings Fast-Tracks Battery Swap Expansion As Loan Process Underway</a>
&#8220;Looking ahead, NaaS will continue to embrace an open and collaborative approach, leveraging digital intelligence and emerging technologies to make EV charging smarter, more convenient, and more efficient,&#8221; said NaaS CEO, Yang Wang.
China&#8217;s new energy vehicle (NEV) production and sales exceeded 12 million units in 2024. As electric vehicle sales surge, EVs have accounted for more than 50% of all new car sales since late 2023. 
This growing demand has made dependable charging solutions essential for automakers. With its vast network, NaaS is strategically positioned to address this need, providing efficient and top-tier aftersales services.
The company uses artificial intelligence to optimize charging efficiency, helping match demand with supply. NaaS's Energy Fintech (NEF) system enhances charging station operations, offering smarter site selection and automated management.
As of third-quarter 2024, NaaS has connected nearly 100,000 charging stations and 1.15 million chargers across&nbsp;China, with its platform serving a total of over 13 million transaction users.
Price Action: NAAS shares traded higher by 10.78% at $1.13 in premarket at last check Monday.
Read Next: <a href="https://www.benzinga.com/25/03/44331117/wayfair-to-open-second-large-format-store-in-atlanta-for-2026">Wayfair To Open Second Large-Format Store In Atlanta for 2026</a>
Photo: Shutterstock

General

NAAS

XIACF

XIACY

Why Is Chinese EV Charging Provider NaaS Technology's Stock Surging Today?

WIIM

ENTX

Entera Bio shares are trading higher after entering a collaboration agreement with OPKO Health to advance a GLP-1/Glucagon candidate.

-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mutation agnostic potential of Actimab-A demonstrated by high rates of Complete Remissions and Measurable Residual Disease Negativity in patients with high-risk features including TP53 mutations and prior Venetoclax treatment
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Actimab-A + CLAG-M combination yielded deep and clinically meaningful responses with expected and manageable safety profile supporting planned pivotal Phase 2/3 trial
NEW YORK, March 17, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M in patients with relapsed/refractory acute myeloid leukemia (r/r AML) have been published in the peer-reviewed journal Leukemia. The publication highlights data including long-term survival outcomes from two-year follow-up and better outcomes in high-risk patients. Actimab-A is a novel targeted radiotherapeutic that uses the Actinium-225 (Ac-225) isotope payload directed against CD33, a marker expressed ubiquitously on AML blasts. The trial was conducted at the Medical College of Wisconsin (MCW) which has extensive experience treating relapsed refractory AML patients with CLAG-M.
Actimab-A + CLAG-M Trial Data Highlights from Publication:
<ul>
<li>18.4 month median Overall Survival (OS) in patients who received 1 or 2 lines of prior therapy</li>
<li>52% of patients in the Actimab-A +CLAG-M trial had TP53 mutations, 56% had prior allogeneic stem cell transplant and 56% of patients had prior Venetoclax therapy</li>
<li>Actimab-A + CLAG-M outcomes compare favorably to the results from historical data with CLAG-M alone in the pre-Venetoclax era from MCW's study (median OS of 13.3 months). Typically, patients who have failed Venetoclax treatment demonstrate median survival between 2.4 – 4.6 months as reported in the literature and the patients with a TP53 mutation even have more dismal survival outcomes. Hence this data supports the use of Actimab-A plus CLAG-M for these patients.</li>
<li>Actimab-A + CLAG-M produced high rates of measurable residual disease negativity (MRD-) including 75% across all patients, 83.3% in patients with a TP53 mutation and 100% in patients with prior Venetoclax therapy</li>
<li>71% of eligible patients received a bone marrow transplant (BMT) and median OS in these patients was 24.05 months</li>
</ul>

Biotech

ATNM

Actinium Pharmaceuticals Announces Publication Of Actimab-A + CLAG-M Trial Results In Patients With Relapsed Or Refractory Acute Myeloid Leukemia In The Peer-Reviewed Journal Leukemia

HC Wainwright &amp; Co. analyst Andrew Fein downgrades Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) from Buy to Neutral and lowers the price target from $12 to $2.

Downgrades

STRO

HC Wainwright & Co. Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2

MGRM

Monogram Technologies shares are trading higher after the company received FDA clearance for the monogram mBôs TKA system.

Stifel analyst Nathan Jones maintains MRC Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) with a Buy and lowers the price target from $17 to $16.

Stifel Maintains Buy on MRC Global, Lowers Price Target to $16

William Blair analyst Andrew Brackmann initiates coverage on Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) with a Outperform rating.

Initiation

BFLY

William Blair Initiates Coverage On Butterfly Network with Outperform Rating

Alpha Modus, a leading innovator in AI-driven retail technology, today announced a groundbreaking settlement in its patent infringement lawsuit against Wakefern and Shelf Nine. As part of this resolution, Alpha Modus and Shelf Nine have reached a settlement agreement, while Shelf Nine's parent company, VSBLTY Groupe Technologies Corp. ("VSBLTY" or "VSBLTY Group Technologies"), and Alpha Modus negotiate a strategic partnership for the deployment of Alpha Modus' cutting-edge technology which would include a perpetual license for Alpha Modus' patented innovations.
The lawsuit—one of several filed by Alpha Modus against major retailers and digital signage networks, including Walgreens, Kroger, Wakefern, Shelf Nine, and Brookshire Grocery—centered on proprietary technology designed to enhance digital engagement and data-driven retail solutions. This agreement not only validates Alpha Modus' intellectual property rights but also establishes a long-term opportunity to integrate Alpha Modus' technology with VSBLTY's proprietary and robust data analytics software once VSBLTY Groupe Technologies and Alpha Modus finalize their strategic partnership agreement.

Legal

AMOD

Alpha Modus Settles Patent Infringement Suit With Wakefern And Shelf Nine; Negotiates Strategic Partnership With VSBLTY Group For Tech Deployment, Terms Not Disclosed

Needham analyst Mike Matson reiterates LivaNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIVN#NASDAQ">LIVN</a>) with a Buy and maintains $64 price target.

Reiteration

LIVN

Needham Reiterates Buy on LivaNova, Maintains $64 Price Target

NAOV

NanoVibronix shares are trading higher on possible continued strength after the company announced on Friday that it published its UroShield study, which showed positive data, including an 86% UTI reduction.

Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) has seen <a href="https://www.benzinga.com/quote/ANET/news">a recent pullback</a> with the stock down about 25% over the past month. But JPMorgan analyst Samik Chatterjee sees it as an opportunity rather than a red flag.
He's adding the stock to the firm&#8217;s Analyst Focus List, pointing to upside potential fueled by AI-driven Ethernet adoption in data centers. &#8220;Investors are overestimating the risks from Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and White Box competitors,&#8221;
Chatterjee stated, maintaining an Overweight rating with a $140 price target — implying a significant upside from current levels.
Arista stock closed the trading day, Friday, at $83.51 a share. That&#8217;s an upside of approximately 68%.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44218719/cisco-nvidia-arista-tackle-tariff-turmoil-whos-best-positioned">Cisco, Nvidia, Arista Tackle Tariff Turmoil: Who&#8217;s Best Positioned?</a>
<h2 class="wp-block-heading">Arista Stock: Pullback Presents A Buy Opportunity</h2>
According to Chatterjee, the recent decline in Arista stock stemmed from broader AI spending concerns among cloud customers and fears of competition from White Box companies. 
However, he argues that these worries are overstated. &#8220;Arista's AI-driven networking demand remains strong, and market fears are not aligned with long-term fundamentals,&#8221; he said. 
Trading at 28x 2026 consensus EPS, Arista stock isn&#8217;t cheap, but with earnings growth ahead and potential multiple expansion, the stock remains well-positioned for gains.
<h2 class="wp-block-heading">Valuation Retraces, But Growth Potential Remains</h2>
While Arista stock&#8217;s premium valuation reflected its high growth expectations, recent weakness has erased much of that premium. Currently trading at 33x next-twelve-month P/E, close to its historical average, Arista stock still offers room for appreciation as AI-related Ethernet adoption accelerates in 2026 and beyond. 
&#8220;We believe the stock&#8217;s premium valuation is justified given its dominant role in high-speed Ethernet switching for AI workloads,&#8221; Chatterjee noted.
<h2 class="wp-block-heading">Seasonal Weakness, But Second-Half Strength?</h2>
Historically, Arista stock underperforms in the first half of the year due to conservative guidance practices. However, the second half tends to see stronger performance, with guidance raises playing a key role. 
&#8220;Our confidence in Arista's second-half rebound remains high, particularly as AI-driven deployments ramp up,&#8221; Chatterjee said. 
Investors looking for AI-driven upside may find upcoming earnings reports to be the catalyst needed to reinforce confidence in the stock's trajectory.
<h2 class="wp-block-heading">Arista Vs. Nvidia: Market Share Concerns Overstated</h2>
A key question among investors is whether Nvidia's dominance in AI networking could hinder Arista's growth. Chatterjee pushes back against this concern, highlighting Arista's strong presence in front-end networks and ongoing market share gains. 
&#8220;While Nvidia dominates the AI accelerator market, Arista continues to win share in the Ethernet switching segment, which remains critical for AI infrastructure,&#8221; he explained. 
Despite some revenue moderation from Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) in early 2024, Arista remains a critical supplier for AI-driven data centers, positioning it well for future growth.
<h2 class="wp-block-heading">The White Box Question</h2>
White Box competitors have maintained a steady market share, but Arista's foothold with major cloud players remains strong. According to Chatterjee, White Box adoption outside top-tier cloud customers is limited due to software complexity, keeping Arista's competitive edge intact. 
&#8220;The software-driven differentiation Arista provides remains a key moat against commoditization,&#8221; he added.
With AI data centers shifting toward Ethernet adoption and Arista&#8217;s long-term growth intact, the current pullback presents an attractive entry point. 
&#8220;We see this as an opportunity for long-term investors, given Arista's clear path to AI infrastructure leadership,&#8221; Chatterjee concluded. As market concerns fade and earnings momentum builds, he sees a compelling case for Arista stock's continued outperformance.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/44005208/nvidia-ai-juggernaut-rolls-on-but-can-arista-cisco-keep-up">Nvidia Dominance Continues As AI Demand Grows: Can Arista, Cisco Keep Up?</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Tech

Trading Ideas

ANET

NVDA

Arista Analyst Sees 68% Upside As Stock Pullback Presents Buying Opportunity

Protalix BioTherapeutics shares are trading higher after the company reported a FY 2024 GAAP EPS beat.

Truist Securities analyst Michael Lewis maintains Sila Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SILA#NYSE">SILA</a>) with a Buy and raises the price target from $27 to $28.

SILA

Truist Securities Maintains Buy on Sila Realty Trust, Raises Price Target to $28

U.S. retail sales showed a rebound in February following a sharp decline in January, yet the pace of the broader recovery fell short of economists&#8217; expectations, underscoring some challenges facing the American economy <a href="https://www.benzinga.com/news/econ-s">in the first quarter.</a>
Retail sales rose 0.2% month-over-month in February 2025, following a downwardly revised 1.2% contraction in January, according to advance estimates from the U.S. Census Bureau released Monday. The figure missed economist projections of a 0.6% increase, as tracked by TradingEconomics.
On an annual basis, retail sales grew 3.1%, slowing from the previous downwardly revised 3.9% growth.
Yet, key data in the report revealed underlying strength across major consumer categories. 
Non-store retailers, a key gauge of online sales, rose by 2.4% month-over-month and health and personal care stores soared by 1.7%. 
Excluding gas stations and auto sales, retail sales rose 0.5% month-over-month, rebounding from January&#8217;s 0.8% decline and outperforming expectations of a 0.4% gain.
The control group measure—which excludes sales from auto dealers, building materials, gas stations, office supply stores, mobile home dealers, and tobacco retailers—climbed 1% in February, fully offsetting January's 1% drop and vastly outperforming the expected 0.2% increase.
<h3 class="wp-block-heading">Market Reaction</h3>
U.S. stock futures rebounded following the retail trade report. As of 8:40 a.m. Eastern Time, S&amp;P 500 futures were down 0.1%, trimming earlier losses.. 
On Friday, the S&amp;P 500—tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)—closed 2.1% higher but still logged its fourth consecutive weekly loss.
Meanwhile, gold futures were up 0.3% extending their rally, after having closed their 10th positive week out of the last 11.
The U.S. dollar Index – a key measure of the greenback's strength – was down 0.1%.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/tech/25/03/44352209/gtc-2025-could-reignite-nvidias-stock-rally-but-only-if-b300-ai-server-roadmap-and-scaling-concerns-are-addressed-says-top-analyst">GTC 2025 Could Reignite Nvidia&#8217;s Stock Rally, But Only If B300, AI Server Roadmap, And Scaling Concerns Are Addressed, Says Top Analyst</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Econ #s

Economics

ETFs

Retail Sales Rebound Less Than Expected In February: Online, Healthcare Spending Show Strong Gains

Truist Securities analyst Richard Newitter maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Buy and lowers the price target from $666 to $605.

ISRG

Truist Securities Maintains Buy on Intuitive Surgical, Lowers Price Target to $605

Harte-Hanks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HHS#NASDAQ">HHS</a>) reported quarterly losses of $(0.33) per share. This is a 22.22 percent decrease over losses of $(0.27) per share from the same period last year. The company reported $47.13 million in sales this quarter. This is a 4.77 percent decrease over sales of $49.49 million the same period last year.

Earnings

Harte-Hanks Q4 EPS $(0.33) Down From $(0.27) YoY, Sales $47.13M Down From $49.49M YoY

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) is a &#8220;meme&#8221; stock and that he doesn't need it because it&#8217;s losing <a href="https://www.benzinga.com/quote/SERV/earnings">too much money</a>.
The company reported weaker-than-expected fourth-quarter results. Adjusted EPS loss of 23 cents missed the consensus estimate for a loss of 18 cents.
&#8220;I'm kind of blown away about how badly the stock acts,&#8221; Cramer said when asked about The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>). &#8220;We get them on, maybe we can get some answers. Otherwise it's going to keep going down I'm afraid. &#8220;
As per the recent news, Trade Desk announced the appointment of Vivek Kundra as CEO, effective March 31.
Jim Cramer recommended buying Louisiana-Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>) here.
On Feb. 19, Louisiana-Pacific reported fourth-quarter net sales growth of 3.5% year-over-year to $681 million, beating the consensus of $666.753 million.
Cramer said Enbridge Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) has &#8220;got so much business in America&#8221; and added that it's a great idea to buy the stock.
In the recent news, Enbridge named Steven W. Williams as chair of the board, effective May 7.
SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) is a &#8220;meme&#8221; stock, Cramer said.
The company announced it will participate in the 2025 Nvidia GPU Technology Conference.
The Mad Money host recommended buying Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>).
Accenture on Thursday announced a strategic investment in OPAQUE, a firm providing a secure AI platform designed to allow organizations to run large-scale, general-purpose AI workloads with encrypted data.
Price Action:
<ul>
<li>Serve Robotics shares jumped 9.1% to settle at $7.66 on Friday.</li>
<li>Trade Desk shares rose 0.1% to close at $53.94 during the session.</li>
<li>Louisiana-Pacific shares gained 2.4% to settle at $91.55.</li>
<li>Enbridge shares rose 0.7% to close at $42.83.</li>
<li>SoundHound AI shares jumped 16.1% to close at $10.34 on Friday.</li>
<li>Accenture shares gained 0.6% to settle at $318.82.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44326690/top-3-materials-stocks-that-may-collapse-in-march">Top 3 Materials Stocks That May Collapse In March</a></li>
</ul>
Photo: Shutterstock

Markets

Media

SERV

SOUN

Jim Cramer Calls This Stock A 'Meme Stock,' Recommends Buying Accenture

Truist Securities analyst Jake Bartlett maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Buy and raises the price target from $200 to $212.

Truist Securities Maintains Buy on Darden Restaurants, Raises Price Target to $212

Management

Press Releases

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

Health Care

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

Comments

aTyr Pharma

Interés en corto

aTyr Pharma (NASDAQ:ATYR) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL